Why the study?
Does recombinant human GH treatment reverse early morphological and functional atherosclerotic changes in GH-deficient adults?
Population
11 GH-deficient (GHD) hypopituitary men (24-49 yr old) and 12 age-matched control men (total n=23).
Comparison
Recombinant human GH for 18 months. vs 12 age-matched control men.
Design
Cohort
Follow-up
18 months
Authors
Loading...
GH treatment was associated with normalized carotid IMT and improved endothelial function in GH-deficient adults; leaves open effects on clinical events pending RCTs.
Does recombinant human GH treatment reverse early morphological and functional atherosclerotic changes in GH-deficient adults?
Growth hormone replacement in GH-deficient men reverses early morphological and functional atherosclerotic changes, potentially reducing vascular risk.
Pfeifer et al. (1999) studied this question.
Synapse has enriched 4 closely related papers on similar clinical questions. Consider them for comparative context: